Business Context and Reporting Period
Company: NeuroOne Medical Technologies Corp (NMTC)
Filing Type: Form 8-K (Current Report)
Date of Report: June 12, 2026
Reporting Period: Event-based report regarding a specific corporate action on the filing date.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on a capital raising mechanism.
Material Changes
The Company filed an updated Prospectus Supplement on June 12, 2026, under its existing "Capital on Demand" Sales Agreement with JonesTrading Institutional Services LLC. This update authorizes the offer and sale of up to $13.4 million of common stock through an "at-the-market" (ATM) offering program.
Guidance, Outlook, and Risks
- Management Commentary: The filing confirms the legal opinion from Honigman LLP regarding the shares and reiterates that the 8-K does not constitute an offer to sell securities in jurisdictions where such an offer would be unlawful.
- Risks/Contingencies: The sale of shares is subject to market conditions and the terms of the Sales Agreement. No specific operational risks or contingencies are detailed in this specific report.
- Unusual Items: None reported beyond the standard ATM program update.
Investor Verification Checklist
- Verify the current share price and potential dilution impact of selling up to $13.4 million in shares.
- Review the full Prospectus Supplement (Exhibit 104 or referenced document) for specific terms of the ATM program.
- Check recent trading volume to assess the Company's ability to execute sales without significant price impact.
- Confirm the Company's current cash position to understand the necessity of this capital raise.